Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MET-224o
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Peptides, Small Molecules
- Administration
- Oral
01
Overview
MET-224o is an oral, fully biased, ultra-long acting glucagon-like peptide 1 receptor agonist (GLP-1 RA) under development for the treatment of obesity and overweight. It is a synthetic peptide designed with technology that enables oral bioavailability and stability in the gastrointestinal tract. Preclinical studies have demonstrated potent and fully biased receptor activation activity, with robust efficacy comparable to other GLP-1 RAs and no significant toxicity observed in early research. The drug was initially developed by D&D Pharmatech and is currently being advanced by Metsera[1][2][3][4].
- Other names
- MET-224oMET224oMET 224o
02
Targets
Beyond the preview
Go deeper on MET-224o.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MET-224o.